Glasdegib for Acute Myeloid Leukaemia (AML) – first line

Acute myeloid leukaemia (AML) is an aggressive type of blood cancer that starts from certain types of young white blood cells called granulocytes or monocytes in the bone marrow. The bone marrow is the soft inner part of the bones, where new blood cells are made. AML usually develops over a few weeks and becomes increasingly more severe. If left untreated it would cause death with a few weeks or months. AML incidence is strongly related to age.
Glasdegib is an oral drug under development for the treatment of AML. It is a drug that has the potential to stop the growth of cancer cells. If licensed, glasdegib may offer an additional treatment option for patients with AML.